Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lupin

- PMLiVE

Boehringer Ingelheim launches new digital innovation team

BI X will aim to accelerate research and development

- PMLiVE

New EU and US approvals for Humira biosimilars

Samsung’s Imraldi and Boehringer Ingelheim’s Cyltezo receives nod from EMA and FDA, respectively

- PMLiVE

Boehringer Ingelheim calls for “strong and united” Europe

Simone Menne highlights the EU's achievements, and her firm's contribution

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

Riding the wave of digital disruption

The challenges and rewards of meeting consumer expectations

Roche Basel Switzerland

Tecentriq growth offsets Avastin’s US decline at Roche

Shifts focus to newer therapies in anticipation of brewing biosimilar competition

- PMLiVE

Sanofi and Boehringer Ingelheim complete €21.8bn asset swap

Exchange of animal health and consumer interests sharpens the firm's focus

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

- PMLiVE

Boehringer says Avastin biosimilar on track as Phase III gets underway

Clinical data suggests candidate has same biologic profile as Roche’s cancer drug

Deal Watch October 2016

Allergan, Astellas, AstraZeneca, Boehringer Ingelheim and Eli Lilly feature in this month's pharma deals round-up

- PMLiVE

Pharma ‘could do better’ on social media engagement

Industry is comfortable with the tech but has work to do on its approach

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links